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Traumatic brain injury (TBI) is currently a major cause of morbidity and poor quality of life in Western 
society, with an estimate of 2.5 million people affected per year in Europe, indicating the need for 
advances in TBI treatment. Within the first 24 h after TBI, several inflammatory response factors become 
upregulated, including the lectin galectin-3. In this study, using a controlled cortical impact (CCI) model 
of head injury, we show a large increase in the expression of galectin-3 in microglia and also an increase 
in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after head injury. We report that 
galectin-3 can bind to TLR-4, and that administration of a neutralizing antibody against galectin-3 
decreases the expression of IL-1β, IL-6, TNFα and NOS2 and promotes neuroprotection in the cortical 
and hippocampal cell populations after head injury. Long-term analysis demonstrated a significant 
neuroprotection in the cortical region in the galectin-3 knockout animals in response to TBI. These 
results suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among 
other proteins, to TLR-4 and promoting inflammation and neuronal loss. Taking all together, galectin-3 
emerges as a clinically relevant target for TBI therapy.
Traumatic brain injury (TBI) has become one of the main causes of death and disability in the Western world, 
where ~160,000 admissions to hospital were catalogued as head injury during the period 2013–14 in the UK (data 
obtained from the Headway brain injury association). TBI pathology results in a complex set of symptoms that 
may lead to long-term impaired cognitive function and dementia, Parkinson’s disease, and amyotrophic lateral 
sclerosis1. Prompt actions in both pre-hospital and early in-hospital stay are considered as key factors to decrease 
mortality and improve the patient’s neurological outcome2. Despite recent advances in the management of TBI, 
its consequences remain significant and often very disabling3.
TBI can be divided into several stages: (i) the primary injury (due to the initial impact, e.g. contusion of 
the brain); (ii) the secondary injury, characterized by the spread of cell loss, diffuse axonal damage and also a 
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multiphasic neuroinflammatory response and (iii) the stage characterized by attempted, but ineffective, regener-
ation and repair. Many of the current efforts to reduce the damage after head injury are focused on the events that 
occur during the secondary injury phase and in particular those regulating the neuroinflammatory response4. 
Although it is well established that the neuroinflammatory process plays an important role during TBI, it is still 
not clear how to modulate it in a manner that provides beneficial results4,5. Recent studies that have focused on 
the inflammatory response after head injury, demonstrate that microglia/macrophages display a mixed pheno-
type as a result of the complex signalling environment instead of a well-defined “M1” or “M2” phenotype6–8. 
Eventually, the M2-like phenotype turns into a more proinflammatory phenotype which increases the cortical 
and hippocampal neurodegeneration8.
Various therapies to treat TBI have been shown in experimental animal models to be effective when they are 
dosed before or soon after TBI9. This highlights the importance of the early events triggered after head injury, 
for TBI progression. One of the first defence mechanisms that is activated after head injury is the innate immune 
response. Activation of members of the Toll-like Receptor (TLR) family has been shown to play an important role 
in different CNS injuries or infections and during the progression of different neurodegenerative diseases10. The 
release of alarmins or damage-associated molecular pattern molecules (DAMPs) upon injury, activates pattern 
recognition receptors (PRRs), such as TLRs11. Among the different TLR members, TLR-2 and TLR-4 have been 
shown to play a key role during the neuroinflammatory response in various experimental models for TBI12–18. 
Therefore, finding treatments to decrease TLR-2 and TLR-4 activation would be therapeutically advantageous.
Galectins are a family of proteins that consist of 15 members with significant sequence similarity in their 
carbohydrate-recognition domain (CRD) with affinity towards β -galactosidases19. Galectin-3 has been shown to 
have different functions depending on cell type and cellular location. Galectin-3 can be found inside the nucleus 
and the cytosol, embedded in the plasma membrane20 or released extracellularly upon exposure to certain stimuli 
such as lipopolysaccharide (LPS)21,22 or IFNγ 23. Galectin-3 appears to function as a master regulator during the 
inflammatory response in neurodegenerative diseases. We have recently demonstrated that galectin-3 is released 
by activated microglia in response to proinflammatory stimuli and importantly, galectin-3 acts as an endoge-
nous paracrine TLR4 ligand22. We also demonstrated that released galectin-3 is essential for the full microglial 
response upon LPS treatment, thus supporting a central role of this galectin in regulating brain immune response. 
Furthermore our previous studies showed that: (i) galectin-3 is involved in the proinflammatory response trig-
gered by α -synuclein in microglial cells24, a hallmark of Parkinson’s disease physiopathology, and (ii) mice lacking 
galectin-3 were more resistant to hippocampal degeneration in a model of global cerebral ischemia that mimics 
the brain damage caused by cardiac arrest22. Regarding the role of galectin-3 under conditions of brain trauma, 
several studies have demonstrated striking early increases in the expression of galectin-3 in different trauma 
models including spinal cord injury25–27 and also in experimental models of TBI28,29. Interestingly, a recent study 
performed in 8 weeks post-contusion spinal cord injured mice, found galectin-3 as one of the most upregulated 
extracellular proteins30, suggesting that galectin-3 plays also a role at later stages of the injury. Consequently, and 
given the important role of galectin-3 in regulating brain inflammation and neurodegeneration, studies aimed to 
elucidate the role of this galectin after TBI are encouraged. In this study, we focus on the role that galectin-3 plays 
during the early neuroinflammatory response driven by microglia cells after head injury.
Results
Galectin-3 is expressed mainly in microglia cells and released after cortical impact. We used 
a cortical contusion mouse model to investigate when and where galectin-3 is expressed after head injury. Total 
RNA was extracted from cortex and hippocampus to quantify galectin-3 levels (Fig. 1a). We found a clear induc-
tion of galectin-3 expression 24 h after impact on the ipsilateral site in both cortex and hippocampus, and the 
levels remained high thereafter, even 3 weeks later (data not shown). Although induction of galectin-3 could 
not be observed 2 h after head injury using qPCR, we found some high galectin-3 expressing cells by immuno-
histochemistry in both cortex and hippocampus (Supplementary Fig. S1). We also investigated whether galec-
tin-3 is released into brain parenchyma after head injury. Consequently, we analysed the content of galectin-3 
in cerebrospinal fluid (CSF) after head injury as compared to naïve animals and we observed a statistically sig-
nificant increase in galectin-3 in the CSF 24 h after the impact (Fig. 1b). We then decided to study which cells 
were predominantly expressing galectin-3 24 h after the injury through an immunohistochemical colocalization 
analysis. We observed that the majority of cells highly expressing galectin-3 were Iba-1 positive cells (Fig. 1b 
and d). To confirm more specifically whether those Iba-1 positive cells expressing galectin-3 were microglia, 
we used the specific microglia marker TMEM11931. This analysis confirmed that microglia express galectin-3 
under conditions of brain trauma (Supplementary Fig. S1). Astrocytes have been shown to be able to express high 
levels of galectin-3 five days post injury (dpi) in a stab wound-injured cerebral cortex32. However, the number of 
GFAP-labelled astrocytes expressing galectin-3 24 h after the contusion was very low (Supplementary Fig. S1). 
Interestingly, we could find a milder punctiform galectin-3 staining present in cells belonging to the pyramidal 
cell layer in the CA1 region on both the ipsilateral and contralateral sites 24 h after injury (Fig. 1d). We also 
observed punctiform galectin-3 containing cells in NeuN positive cells in the cortex (Supplementary Fig. S1). 
Neuronal expression of galectin-3 has already been described in cultures of mouse dorsal root ganglion (DRG) 
neurons33 and also in the developing and adult CNS in a subset of DRG neurons in the spinal ganglia34.
The hippocampal formation, which is organized into very well defined neuronal layers, is highly affected by 
head trauma, thus allowing the study of interactions between reactive microglia and neurodegenerative processes. 
Iba-1 immunohistochemistry clearly demonstrated the presence of reactive microglia (based on morphological 
features) in the ipsilateral and contralateral hippocampus (Fig. 1d), especially when compared to sham (craniot-
omy) controls. Strikingly, the expression of galectin-3 was restricted to the ipsilateral cortex and hippocampus 
(compare TBI ipsilateral side versus contralateral side in Fig. 1c and d). Most galectin-3 expressing cells were iba-1 
positive (Fig. 1c and d). Interestingly, these galectin-3 positive cells were consistently present in the degenerating 
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ipsilateral hippocampal neuronal cell layers (see the high number of expressing cells invading the ipsilateral CA1 
area in Fig. 1d compared with the contralateral side).
Interestingly, some of the Iba-1 positive cells were apparently surrounding other cells within the CA1 region 
(see detail in Fig. 1d). Microglia can remove dead, dying and stressed neurons in a process termed phagoptosis35. 
Since galectin-3 is released after trauma, and the phagocytic microglial receptor MerTK has been shown to bind 
galectin-3 acting as an opsonin35 we wondered if exogenous galectin-3 participates in the phagocytic response 
Figure 1. Galectin-3 is highly expressed and released in the brain after TBI in a cortical contusion murine 
model. qRT-PCR analysis of galectin-3 expression at 2 and 24 h after TBI in the cortex and hippocampus (a). CSF 
protein levels of galectin-3 at 2 and 24 hours after TBI (b). Images showing colocalization of galectin-3 positive 
cells with Iba-1 in sham, TBI contralateral and TBI ipsilateral in Cortex (c) and Hippocampus (d) 24 h after TBI. 
Statistics and error bars: mean ± s.d. n = 4 for A and n = 5 for B. Data were analyzed using a two-sided Student’s 
t-test. * p < 0.05, ***p < 0.001 and ****p < 0.0001. Scales bar for c is 100 μ m and for d is 50 μ m. Arrowheads 
define the area of neuronal cell bodies in the CA1 region. Hoechst was used to counterstain the nuclei.
www.nature.com/scientificreports/
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driven by microglia cells. To test our hypothesis, we pre-treated a murine microglial cell line (BV2) with recom-
binant galectin-3 for 18 h to assess the effect on the phagocytic response towards neuronal debris. We observed 
a remarkable 4-fold increase in the phagocytic capacity of BV2 cells in those cells pre-treated with galectin-3 
compared to control (Supplementary Fig. S1). We decided then to analyse the capacity of recombinant galectin-3 
to induce neuronal loss in rat primary mixed glial cultures (85% neurons). We observed a decrease in neuronal 
survival after 96 h treatment with recombinant galectin-3 (Supplementary Fig. S1). These results demonstrate 
the involvement of galectin-3 in the microglial phagocytic response and support its potential role in primary 
phagocytosis or phagoptosis35.
Recently, our group has demonstrated that the released form of galectin-3 may act as a TLR4 agonist induc-
ing a proinflammatory response under ischemic conditions22. We wanted to know whether the released form of 
galectin-3 after contusion might play also a role as a TLR-4 ligand22. For this reason, we analysed the interaction 
between TLR4 and galectin-3 through an immunoprecipitation approach. Protein extracts obtained from naïve, 
2 h and 24 h CCI-injured mice were immunoprecipitated overnight with a TLR-4 antibody. The immunopre-
cipitate was collected and run on a gel, and then transferred into a nitrocellulose membrane. After that, the 
membrane was immunoblotted with a specific galectin-3 antibody. The results showed an interaction between 
galectin-3 and TLR4 at 24 h but not at 2 h after injury (Fig. 2a, cropped blots, full-length blot is presented in 
Supplementary Fig. S2) in correspondence with the TBI-induced released levels of galectin-3 as measured in the 
CSF (Fig. 1b).
Galectin-3 neutralising antibodies reduce inflammation, microglial activation and neuronal 
loss after head injury. To further study the role of the released form of galectin-3 during the inflammatory 
response, we injected into the contused cortex 0.5 μ g of either neutralizing antibody against galectin-3 or control 
isotype antibody (total volume injected was 5 μ l at a rate of 1 μ l/min) 1 hour after the contusion. We assessed the 
effect of the neutralizing antibody on neuronal survival in the cortex and hippocampus and the inflammatory 
response 24 h after injury. Interestingly, we observed a neuroprotective effect of galectin-3 neutralizing antibody 
in the cortex and hippocampus 24 h after head injury (Fig. 2b,c). TBI triggers a very potent neuroinflammatory 
response which is responsible for many of the deleterious effects during secondary injury36. Microglia and mac-
rophages express both M1 and M2 markers early after injury, but with time, the transient upregulation of M2 
markers is replaced by a more M1-like phenotype8. Consequently, we analysed the mRNA levels of key M1 and 
M2 markers in response to neutralizing or control isotype antibodies 24 h after brain trauma. Treatment with 
galectin-3 neutralizing antibody reduced the trauma-induced increases of the different proinflammatory markers 
IL-1β , IL-6 and NOS2 (Fig. 2d–f). In contrast, neutralizing antibodies failed to alter the trauma-induced mRNA 
expression of the M2 markers Ym-1, Arg-1 and TGF-β (Fig. 2g–i). It is well known that microglia activation is 
accompanied by graded morphological alterations; thus early-stage activation is characterized by increased ram-
ification of cytoplasmic processes, cell size and enhanced Iba-1 expression. After that, it is followed by further 
thickening of processes and retraction of the finer ones and increased cell body size to end up with a complete 
retraction of cytoplasmic processes, thus acquiring amoeboid-shape morphology. We analysed the effect that 
the injection of the galectin-3 neutralizing antibody had on different microglia morphology features 24 h after 
head injury. The results showed that microglia in mice injected with the neutralizing antibody exhibited a less 
“amoeboid” morphology with higher numbers of secondary branches and triple and quadruple junction points as 
compared to microglia from animals treated with IgG isotype control antibody (Supplementary Fig. S3).
Genetic knockout of galectin-3 reduces neuronal loss after head injury and changes micro-
glial morphology. Galectin-3 can play diverse roles in the regulation of different processes such as prolif-
eration, adhesion, migration, invasion, angiogenesis, apoptosis and inflammation37–39. It is noteworthy that in 
some of these processes opposite effects have been reported (as for instance in the control of the inflammatory 
response)23,40, due to a different location within the cell and/or posttranslational modification. We wanted to 
analyse the effect that depletion of galectin-3 could have over the neuronal population after head injury using 
galectin-3 knockout mice (Fig. 3a). We first decided to analyse the survival of the neuronal population by analys-
ing the number of NeuN-positive cells in three different regions (Cortex, CA1 pyramidal cell layer and Dentate 
Gyrus -DG-) within the first 24 h after injury. The results showed that lack of galectin-3 is neuroprotective within 
the first 2 h in the cortical region (Fig. 3b), while in the case of the hippocampal area we needed to wait until 
24 h to observe a neuroprotective effect in the CA1 and DG regions (Fig. 3c,d). Figure 3e shows representative 
images of the three different regions (cortex, CA1 pyramidal layer and DG) in wild type and galectin-3 knock-
out mice within 24 h after contusion. We wanted to know if this neuroprotective effect within the first 24 h was 
long-lasting. For that reason, we analysed using toluidine blue staining the area of loss in the cortex 21 days after 
injury (Fig. 3f,g) in wild type and galectin-3 knockout mice. We found that lack of galectin-3 protected against the 
long-term TBI-induced cortical damage, confirming the observed neuroprotective effect at earlier time points.
We analyzed the neuroinflammatory response through the expression of several factors responsible for induc-
ing either a proinflammatory or a supportive environment (Fig. 4) in the cortex and hippocampus early after 
impact. Most remarkable effects were found in the M2 markers analysed. Specifically, galectin-3 deficiency fur-
ther increased the trauma-induced mRNA up-regulation for arginase-1 (Arg-1) in the hippocampus at 24 h and 
of Ym-1 in the cortex at 2 h (Fig. 4d,e). We also analysed two key neurotrophins, BDNF and NGF. Interestingly, 
galectin-3 knockout animals exhibited significantly higher cortical mRNA levels of BDNF as compared with 
wild type animals after trauma (Fig. 4f), while NGF remained unaltered (Supplementary Fig. S4). Regarding the 
pro-inflammatory response, TBI did up-regulate all markers analyzed, including IL-1β , TNF-α and NOS-2 in the 
cortex and hippocampus in WT animals (Fig. 4a–c). Unexpectedly, galectin-3 deficiency exacerbated transiently 
the trauma-induced upregulation of all M1 markers in cortex 2 h after injury (Fig. 4a–c). This highlighted a dis-
crepancy in the immune response to TBI between galectin-3 deficient mice and mice injected with anti-galectin-3 
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Figure 2. Effect on the inflammatory response and neuronal survival after TBI in mice injected with 
neutralising antibody against galectin-3 compared to isotype IgG control . Analysis of the binding of 
TLR-4 and galectin-3 in the whole tissue extract at different time points after immunoprecipitating with TLR-4 
antibody (a) followed by incubation with TLR-4 antibody (a, upper panel) or with galectin-3 antibody (a, lower 
panel). Immunohistochemistry of NeuN (b) and quantification (c) in the cortex and hippocampus of mice 
injected with neutralising antibody against galectin-3 or isotype control. Quantification of the gene expression 
in whole tissue for IL-1β (d), IL-6 (e), NOS-2 (f), Ym-1 (g), Arg-1 (h) and TGF-β (i). Statistics and error bars: 
mean ± s.d. n = 4 for c, n = 7 for (d–i). Data were analysed using two-sided Student’s t-test. *p < 0.05. Scale bar 
in b is 250 μ m.
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neutralising antibody. This may be explained by the difference between a total constitutive genetic deficiency 
of galectin-3, affecting all cell types and compartments, versus a model using a neutralising antibody against 
galectin-3, affecting only extracellular galectin-3.
Rod microglia have been shown to play a role during the proinflammatory response in two different experi-
mental models of head trauma41,42. Consequently, we decided to analyse the number of rod microglia early after 
head trauma. We focused on two areas where the appearance of the rod microglial cells (CA1 and the somatosen-
sory cortex) has been described after head trauma. We observed a decrease in the presence of rod microglia in 
Figure 3. Effect of the lack of galectin-3 on the neuronal survival in cortex and hippocampus after TBI. 
Chart comparing the expression of galectin-3 between wild type and galectin-3 knockout mice in the ipsilateral 
cortex 24 h after injury (a). Comparison of NeuN-positive cells between wild type and galectin-3 knockout 
mice after TBI in the cortex (b), CA1 (c) and dentate gyrus (d). Representative pictures of NeuN in different 
regions (e). Representative image of toluidine blue staining in wild type and galectin-3 knockout mice (f) and 
quantification of the cortical tissue loss (g) 21 days after injury. Statistics and error bars: mean ± s.d. n = 4 for 
(a–d) and (g). Data were analysed using two-sided student’s t-test. *p < 0.05 **p < 0.01 and ****p < 0.0001. Scale 
bar in e is 100 μ m and for f is 1000 μ m.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:41689 | DOI: 10.1038/srep41689
the galectin-3 knockout mice (Supplementary Fig. S4), and of microglia positioned along the axons of neurons 
(Supplementary Fig. S4).
Discussion
One of the major challenges in TBI research is to identify new therapies or molecules that improve the patient’s 
neurological outcome after injury. The secondary injury occurring after TBI contributes to a worsening of the 
Figure 4. Assessment of the inflammatory response in wild type and galectin-3 knockout mice after TBI. 
Analysis of the gene expression on the ipsilateral side of the isolated cortex and hippocampus in wild type and 
galectin-3 knockout mice for IL-1β (a), TNF-α (b) and NOS-2 (c), Arginase-1 (d), Ym1 (e) and BDNF (f). 
Statistics and error bars: mean ± s.d. n = 5. Data were analysed using a two-sided Student’s t-test followed by 
one-way ANOVA with post-hoc Fisher’s least significant difference (LSD). *p < 0.05 **p < 0.01.
www.nature.com/scientificreports/
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neurological outcome in addition to the initial contusion. Identifying factors that regulate the TBI-induced neu-
roinflammatory response could generate candidates for therapies.
Soon after a head or spinal cord injury, the expression of several proteins related to the inflammatory response 
is upregulated, including the lectin galectin-325–29. The neuroinflammatory response triggered by TBI is believed 
to be a major determinant of the secondary cell death after brain trauma. We have previously demonstrated 
that reactive microglia release galectin-3, thus playing a major role in the microglial immune response dur-
ing ischemia22. Our goal in this study was to investigate the role of galectin-3 during head injury, and whether 
there was any release of galectin-3 after TBI. The idea that there could be an increase in the released form of 
galectin-3 after head injury was suggested by different studies demonstrating an increase in the levels of galectin-3 
in plasma after TBI43,44. Interestingly in one of these studies, the authors found a positive correlation between the 
galectin-3 levels in human plasma and the Glasgow Coma Scale (GCS) scores43. In our study, we found significant 
amounts of galectin-3 in the mouse CSF 24 h after injury. The blood brain barrier is highly disrupted immediately 
after head injury45, therefore a substantial leakage of galectin-3 from the brain parenchyma into the CSF can be 
expected.
Our next goal was to identify which cell types express galectin-3. Confocal immunofluorescence using 
antibodies to TMEM119 (specific to microglia31), Iba-1 (microglia and macrophages), GFAP (astrocytes) and 
NeuN (neurons) along with galectin-3 antibodies led us to confirm that: (i) Iba-1 positive cells are the main cells 
expressing galectin-3, (ii) reactive microglia, as demonstrated by TMEM119 expression, have also high levels of 
galectin-3, (iii) the majority of astrocytes lack galectin-3 expression within the first 24 h after impact, and (iv) 
most neurons do not express galectin-3, but unexpectedly certain neuronal cell types cells do express galectin-3.
We investigated the role(s) that extracellular galectin-3 may play during TBI. We have recently described a 
new role for released galectin-3 as an endogenous ligand for TLR-4, triggering a TLR-4-dependant neuroinflam-
matory response22. In our TBI model we observed that galectin-3 binds to TLR-4. Importantly, TLR-4 activation 
has been shown to modulate the early neuroinflammatory response after head injury, and inhibition of TLR-4 
promotes a better neurological outcome15–17. By using a neutralizing antibody against galectin-3 we could observe 
a decrease in the expression of IL-1β , IL-6 and NOS2 but no difference in any of the M2 markers upon head 
injury.
There are studies where galectin-3 has been described to act as opsonin/bridging molecule by simultaneously 
binding to Mer receptor tyrosine kinase (MerTK) and “eat-me” signals on neurons thereby stimulating phagocy-
tosis35,46,47. Hence, one or more roles for the extracellular galectin-3 could occur at the same time in our model. 
The possibility that released galectin-3 may have an important role in modulating phagocytosis is certainly attrac-
tive. Consistent with this view we observed the presence of highly expressing galectin-3 reactive microglia/mac-
rophages close to hippocampal cells and restricted to the pyramidal cell layer, which is highly sensitive to brain 
trauma. To ascertain a potential role of galectin-3 in promoting phagocytosis, we conducted in vitro culture assays 
using the microglial cell line BV2 exposed to TAMRA-labelled neuronal debris and pre-treated with exogenous 
galectin-3. FACS analysis demonstrated a positive role of exogenous galectin-3 in promoting microglial phago-
cytosis of neuronal debris. We also found that exogenous galectin-3 increased cell death in primary mixed glial 
cultures. Since phagocytosis can be extended to viable neurons, a process known as primary phagocytosis or pha-
goptosis, the possibility that galectin-3 participates in this process is plausible. Our results suggest an involvement 
of galectin-3 during the phagocytic response after TBI, but still more in depth studies are required to confirm this 
hypothesis.
Once we established a potential role of galectin-3 in promoting phagocytosis and cell death, we next analysed 
the potential effect of galectin-3 gene deletion in mice subjected to contusion TBI. A significant protection of 
cortical and hippocampal neurons was found in animals lacking galectin-3 at early and late time points (21 days) 
supporting our hypothesis that galectin-3 plays a deleterious role early after head trauma conditions.
We and others have studied the immunomodulatory properties of galectin-3 towards the two opposite polar-
ization states of microglia or macrophages21–24. TBI induces a complex environment where a mixed inflamma-
tory response (M1 and M2 phenotypes) develops early after injury6–8. We observed a similar pattern in our own 
analysis of the inflammatory response. Consequently, we analysed the effect of galectin-3 gene deletion on dif-
ferent markers of microglia polarization including IL-1β , TNF-α and NOS-2 (M1) and arginase-1 and Ym-1 
(M2) in response to TBI. Unexpectedly, galectin-3 gene deletion failed to modify the trauma-induced proin-
flammatory response, thus contrasting with the anti-inflammatory effect of galectin-3 neutralizing antibodies. 
However, it should be stressed that the hippocampus exhibited a dramatic increase in classical M2 activation 
markers 24 h after trauma (i.e. arginase-1). The reason for this discrepancy may be a consequence of the pleth-
ora of functions of galectin-3 depending on where it is located within the cell (released, cytosolic or nuclear) 
and the cell type in which it is expressed20–23,32. The disparity observed in terms of M1 markers in response to 
either galectin-3 deletion (intra and extracellular) or neutralizing antibodies (extracellular) highlights the com-
plex galectin-3-dependent cellular interactions that regulate brain immune functions. Galectin-3 gene deletion 
decreased the number of “rod microglia” shortly after brain trauma, thus supporting a role of galectin-3 in the 
proinflammatory response to brain trauma. Our study demonstrates that galectin-3 could be working as an 
endogenous ligand for TLR4 24 h after brain trauma, at a time post-injury when galectin-3 mRNA and protein 
levels are high. These results suggest that galectin-3 might be, together with other DAMPs, responsible for the 
full activation of different immune cells via TLR activation within the first 24 h. Therapies aimed at modulating 
galectin-3 expression or availability within the first 24 h after injury might have a potentially positive effect on 
patients’ outcome at later time points (as was observed in the galectin-3 knockout mice 21 days after injury).
Overall, we conclude that galectin-3 acts as an alarmin under conditions of brain trauma, and induces a strong 
proinflammatory response, most likely through TLR4 activation, and might be involved also in the phagocytic 
response. Considering that the facilitation of M2 activation may be a promising strategy to promote tissue repair 
under conditions of brain trauma, pharmacological inhibition of galectin-3 deserves special attention. In support 
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of this view, galectin-3 gene deletion further exacerbated the trauma-induced M2 response in the hippocampus. 
Aside from exhibiting enhanced phagocytosis, the M2 phenotype is associated with the release of trophic factors. 
We decided to analyse the effect of brain trauma and galectin-3 gene deletion on the mRNA levels of NGF and 
BDNF. We did not find any differences in the levels of NGF but strikingly, the lack of galectin-3 markedly increased 
the cortical mRNA levels of BDNF in response to brain trauma, with no response in the hippocampus. BDNF can 
be synthetized not only in neurons but also in astrocytes48 and microglia49. We could not observe changes in BDNF 
expression in mice treated with neutralizing antibody against galectin-3 (data not shown), suggesting that only intra-
cellular galectin-3 is responsible for changes in BDNF expression. At the time point at which BDNF was upregulated 
(24 h), the majority of cells expressing galectin-3 were either neurons or microglia but not astrocytes. This suggests 
that the source of BDNF is either neuronal and/or microglial but not astrocytic at the time examined.
BDNF is strongly up-regulated shortly after TBI in the hippocampus and cortex50,51 which supports a trophic 
role of this neurotrophin after neurotrauma conditions. Consistent with this view, several studies have demon-
strated a beneficial effect of BDNF administration in different spinal cord injury models52–54. Furthermore, small 
molecule BDNF mimetics which specifically bind and activate trkB receptors, have been shown to improve motor 
learning after TBI54 and have neuroprotective effects in adult55,56 and newborn57 mice after CCI. Our results sug-
gest an inhibitory role of galectin-3 on BDNF expression after head injury and add new evidence supporting the 
potential of anti-galectin-3 therapy in TBI.
In conclusion, our study demonstrates that galectin-3 is expressed and released predominantly by microglial 
cells in response to TBI, thus acting as an alarmin. The detrimental role of galectin-3 early after TBI was corrobo-
rated using galectin-3 knock-out mice and neutralizing antibodies, which conferred neuroprotection in response 
to TBI. Once released, galectin-3 binds to and activates TLR4, thus inducing a proinflammatory response and 
perhaps also enhancing the phagocytic response. Our data also suggest an important role of galectin-3 in regulat-
ing the M2 polarization state and BDNF mRNA expression after TBI.
Methods
Animals. All experiments conducted in Seville were approved by The University of Seville Ethical Committee 
for Experimental Research and fulfilled the requirements for experimental animal research in accordance with 
the Guidelines of the European Union Council (86/609/EU) and the Spanish regulations (BOE 34/11370–421, 
2013) for the use of laboratory animals. All the experiments performed in London were approved by the Queen 
Mary University of London Animal Welfare and Ethical Review Body and carried out under Licence from the 
UK Home Office in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 for the use 
of animals in research and Directive 2010/63/EU. All experiments performed in Cambridge were performed 
in accordance with the UK Animals (Scientific Procedures) Act (1986) and were approved by the Cambridge 
University local ethical committee.
10–12 week-old not littermate wild type and galectin-3 null mutant mice on the C57BL/6 background58 were 
obtained from Dr. T. Deierborg from Lund University. 10–12 week old CD-1 (IRC) outbred mice were purchased 
from Charles River Laboratories. Animals were housed under a 12 h light/dark cycle with free access to food and 
water.
Genotyping. The genotype of gal3− /− and gal3+ /+ mice was determined by analysis of DNA extracted 
from the tails using a QuickExtractTM (Epicentre) and amplified with the MyTaqTM Red DNA Polymerase 
(Bioline). The PCR consisted of 94 °C for 1 min, then 35 cycles with denaturation at 95 °C for 15 sec, annealing at 
58 °C for 15 sec, and elongation at 72 °C for 10 sec.
The primer sequences used were obtained from a previous study59: galectin-3 common 5′ -CAC GAA CGT 
TTG CTC TCT GG-3′ ; galectin-3− /− 5′ -GCT TTT CTG GAT TCA TCG ACT GTG G-3′ (product size on a gel: 
384 bp) and galectin-3+ /+ 5′ -TGA AAT ACT TAC CGA AAA GCT GTC TGC-3′ (product size on a gel: 300 bp).
Surgery. Mice were anaesthetized with a mixture of ketamine (50 mg/kg) and medetomidine (10 mg/kg) 
intraperitoneally (i.p.) and given pre-emptively analgesia with buprenorphine (0.05 mg/kg) subcutaneously (s.c.). 
Once surgical anaesthesia was confirmed, mice were placed into a stereotaxic frame and secured with teeth bar 
and guinea pig ear bars. A midline incision was made to expose the skull and a 3.0 mm craniotomy was made 
over the right parietal bone (central point was at − 2.0 mm bregma, 2.5 mm lateral) using a 0.5 mm diameter burr 
bit connected to a hand held dental drill. Care was ensured so that the dura mater was undisturbed during the 
drilling and the removal of the skull flap.
The contusion was carried out using the Hatteras PinPoint controlled cortical impactor (Hatteras Instruments, 
USA). Parameters used were: 3.0 m/s velocity, 100 ms dwell time, and 2.2 mm impact depth at 20° angle. Sham 
injury mice received a craniotomy only. After the injury, the skull bone flap was replaced, skin sutured and placed 
into a warm incubator (27–28 °C) to recover.
In another study, agents were administered intracerebrally at 1 h post injury (final volume 5 μ l of either 
galectin-3 neutralising antibody or IgG isotype control during 5 minutes at a rate of 1 μ l/min; the concentration 
of the antibodies was 0.1 μ g/μ l). After the TBI surgery, the animal was transferred to a post-operative chamber 
and kept warm during the 1 h period prior to the injection into the brain. Ten minutes prior to the intracerebral 
injection, a top up of anaesthesia was provided to ensure the mice were fully surgically anaesthetized. The mice 
were secured into a stereotaxic frame and once the injury site was revealed agents were injected similarly to previ-
ously described60. Briefly, using a glass micropipette, 5 μ l of agent was injected directly into the injury epicentre at 
a speed of 1 μ l/min and depth of 1.5 mm, avoiding the hippocampus due to the swelling of the cortex. After injec-
tion, the glass micropipette was slowly withdrawn, the skull bone flap gently placed over the site, and the skin was 
sutured. Approximately 40 min after the last dose of the anaesthetic drug, antipamezole (Antisedan, 2 mg/kg, s.c.) 
and sterile saline (100 ml/kg, s.c.) was administered to reverse the anaesthetic effect and prevent dehydration, 
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respectively. Post-operative care involved daily weight monitoring and twice daily administration of buprenor-
phine (0.05 mg/kg, s.c.) until there was weight gain or when culled at a defined time point.
At different time-points after the surgery, mice were put under deep anaesthesia before transcardially perfused 
with 4% paraformaldehyde solution for immunohistochemistry analysis. Mice whose brains were used to extract 
RNA or proteins extracts were transcardially perfused with PBS and the brains were quickly dissected and fast 
frozen.
Cell culture. Murine microglial BV2 cell line (passage < 30) was cultured as previously described22. Primary 
mixed neuronal/glial cultures were prepared from cerebella of postnatal day 5 to 7 Wistar rats (male and 
female). Neurons were plated at a density of 5 × 105 cells per well in a 24-well plate and medium was changed 
once 24 hours after the cells were seeded. The cell cultures were left for one week before treatment. The approx-
imate composition of the mixed cultures is 85 ± 5% neurons, 7 ± 3% astrocytes, and 5 ± 3% microglia. For 
live-cell counts, cultures were incubated with the nuclear stains Hoechst 33342 (5 μ g/ml) and propidium iodide 
(1 μ g/ml); Alexa 488-tagged isolectin-B4 (1 μ g/ml) was used to distinguish microglia. Healthy and apoptotic 
(chromatin-condensed) neurons were recognized by their distinct nuclear morphology, whereas propidium 
iodide-positive cells (indicating membrane permeabilization) were identified as necrotic. Cell densities were eval-
uated using a Leica DMI6000 CS microscope. Four microscopy fields per well were quantified (around 150–200 
neurons per field in control conditions), and experiments were performed with three independent culture 
preparations.
Phagocytosis assay. Phagocytosis assays were performed as previously described61. Dead neurons and neu-
ronal debris were obtained by scraping cells from live neuronal-glial culture (85% neurons), and then passing 
cells 10 times through a 0.4 × 13 mm needle. The resulting dead neurons and debris was stained with the suc-
cinimidyl ester of 5-carboxytetramethylrhodamine (TAMRA), and 30 μ g of protein was added to BV2 microglia 
for 2 hours. Microglia were then washed, and the uptake of dead neurons and debris into microglia quantified by 
flow cytometer (Accuri C6 flow cytometer, BD) as the mean fluorescence in the red channel (FL3) per cell (10,000 
cells analysed per well). Where indicated, BV-2 cells were treated ± 200 nM galectin-3 (Sigma catalogue number 
G-5170) for 18 hours prior to addition of neuronal debris into the culture medium.
Immunohistochemistry. Coronal sections between Bregma + 0.50 to − 4.04 were cut at 20 μ m using a cry-
ostat which contained the impact site and were thaw mounted onto gelatinised Superfrost Plus slides. Sections 
that correspond to injury epicentre and penumbra were subjected to antigen retrieval with antigen unmasking 
solution (H-3300, Vector Labs) at 95–100 °C for 20 min followed by another 20 min at room temperature. For 
those sections developed using the chromogen 3,3′ diaminobenzidine (DAB), there was an extra incubation step 
afterwards for 15 min in a solution of 3% H2O2 diluted in 100% methanol to quench the endogenous peroxidase 
activity. Thereafter, the sections were blocked at room temperature in PBS-0.1% Triton X-100 with 10% normal 
donkey serum (Jackson Labs, UK). Later on, the slides were incubated with the indicated primary antibodies 
specified in the Supplementary Table S1. Slides were washed 3 times with PBS, and then incubated with the 
appropriate secondary antibodies (Supplementary Table S2) followed by one-hour room temperature incubation 
with the Vectastain ABC kit (Vector laboratories, catalogue number PK-4000) for the immunohistochemistry 
developed with DAB. The peroxidase reaction was visualized using the DAB Peroxidase (HRP) Substrate Kit 
(with Nickel), 3,3′ -diaminobenzidine (Vectashield) reaction for 2–5 min. For DAB immunohistochemistry we 
employed a NanoZoomer-XR Digital slide scanner (Hamamatsu, Japan).
For fluorescent immunostaining, the staining process of slides was similar to DAB staining, but fluorescent 
secondary antibodies were used (Supplementary Table S2). Hoechst was used to counterstain the nuclei. For the 
visualization and analysis of the immunofluorescence we used a Zeiss upright 710 confocal microscope with a 
Meta spectral head and a Leica epifluorescence microscope.
Immunohistochemistry data analysis. Cortical and hippocampal measurements of the cell death and 
neuroinflammatory response following cortical impact were performed on 3 different regions (0.263 mm2 each 
region) in the ipsilateral cortex and in the different hippocampal subregions Cornu Ammonis 1 (CA1), and 
dentate gyrus (DG). Viable pyramidal neurons were identified as NeuN-positive cells with typical round homog-
enous immunoreactivity; the microglial distribution was quantified using Iba-1 staining. The quantitative analysis 
was carried out by performing a manual assessment of viable neurons using a 20x objective. The final numbers 
were obtained by multiplying the number of NeuN positive cells counted by the area sampling fraction. Four cor-
onal brain sections per animal were quantified at four different bregma levels (− 1.06 mm, − 1.46 mm, − 2.10 mm 
and − 2.46 mm), to give a total number of viable NeuN-positive cells. For quantification of rod microglia, a picture 
of a region of 1.1 mm2 in the CA1 and the somatosensory cortex regions was taken. The total cell number of rod 
microglia, defined as Iba-1 positive cells with highly polarized processes, was manually quantified and normal-
ized to the area of the region of interest.
RT-PCR analysis. Total RNA was extracted using the TRIzol reagent (Sigma Aldrich) following the manu-
facturer’s instructions. Using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, UK), 0.5 μ g of 
the total RNA was transformed into cDNA. Quantitative RT-PCR was performed using the MESA BLUE SYBR® 
Assay (Eurogentec, UK) and primers listed in Supplementary Table S3. Results were calculated using the delta Ct 
method and represented as absolute values with arbitrary units.
Measurement of galectin-3 in the cerebrospinal fluid (CSF) in mice. Cerebrospinal fluid samples 
were obtained from the cisterna magna using an insulin syringe in deeply anesthetised naïve, and at 2 and 24 h 
after head injury. Approximately 5 μ l of CSF was obtained and fast frozen with dry ice and kept at − 80 °C for 
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further analysis. The amount of galectin-3 released present in the CSF from 3 μ l samples was analyzed using the 
galectin-3 kit (Cat No. 12684, BG-Medicine, USA).
Immunoprecipitation. The physical interaction between galectin-3 and TLR-4 was determined by immu-
noprecipitation analysis of brain tissue. The amount of 2.5 mg protein per sample was immunoprecipitated. We 
followed the method previously described22. Cells are lysed after treatment, homogenized with one pulse of 30 s 
sonication, and pelleted by centrifugation in buffer containing 20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1% Triton 
X-100, 2 mM EDTA, 1 μ M p-amidinophenylmethanesulfonyl fluoride hydrochloride, 50 mM NaF, and 10% glyc-
erol. The supernatants are pre-cleared with Dynabeads (Thermo Fisher Scientific) for 4 h at 4 °C. Later on, the 
cleared supernatants are incubated with 2.5 μ g of anti-TLR4 antibody and normal rabbit IgG (R&D systems) as 
a negative control overnight. The next day, the lysates are incubated with Dynabeads for 4 h at 4 °C. The immu-
noprecipitate were washed four times with buffer containing 50 mM Tris-HCl, pH 7.5, 0.1% SDS, 1% NP-40, and 
62.5 mM NaCl and subsequently dissolved in denaturing sample buffer. All cell extracts were processed for immu-
noblotting with a SDS-polyacrylamide gel electrophoresis as described in a 12% Acrylamide/Bis-acrylamide gel.
Image capture and analysis. The quantification of microglia morphology was performed using a specially 
written script for the ImageJ analysis program (ImageJ 1.50d, National Institutes of Health, Bethesda, Maryland), 
and incorporating the ImageJ plugin “AnalyzeSkeleton”. AnalyzeSkeleton counts branch points (junctions) and 
branch length in cells following skeletonization. A 163 × 102 μ m frame was placed over different areas of interest 
in the hippocampus. Twenty cells per treatment were analysed using the script, to quantify the number of second-
ary branches and single, triple and quadruple junctions.
Quantification of the cortical tissue loss. The macroscopic images of the coronal brain sections 
(between bregma + 0.5 to − 4.04) from 21 days post traumatic brain injury stained with toluidine blue, were cap-
tured on a digital eyepiece camera via a dissecting microscope. Briefly, sections were air dried and rinsed shortly 
in distilled water. After that, the slides were submerged in a solution of 300 ml of 70% EtOH with 5 ml of 0.2 M 
acetic acid for 2 hours. Thereafter, slides were incubated in a filtered 0.1% toluidine blue solution for 10 minutes 
and rinsed 3 times with 1 minute distilled water washes. Slides were dehydrated through a series of 2 minutes 
washes with increasing concentration of ethanol (1x with 70% EtOH, 2x with 96% EtOH and 3x with 99% EtOH). 
After a further 3 × 5 minutes incubation in 100% xylene, the slides were mounted using DPX mounting media. 
The brain images were taken from 3 slides per animal, each slide containing 4–5 sections. Images were analysed 
using ImageJ software. The region of brain tissue loss was drawn around in reference to the contralateral side of 
the brain section, and the area was converted to mm2 based on measurements captured on a graticule. Statistical 
analysis was carried out using Student’s t-test from n = 4 animals per group.
Statistical Analyses. The differences between control and experimental groups were evaluated with two 
sided-t-tests or one-way ANOVA with post-hoc Fisher’s least significant difference (LSD) or Tukey’s analysis 
(more than 2 groups) where appropriate, with P < 0.05 was considered statistically significant.
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